INTRODUCTION
There is now a substantially reduced length of hospital stay in patients with a diagnosis of myocardial infarction and ST-segment elevation 1 . Significant reduction in health cost associated with this strategy has been consistently found [2] [3] [4] . At the time when this study was designed, the Guidelines of the European Society of Cardiology (ESC) recommended that early discharge (after around 72 h) after myocardial infarction (MI) with ST-segment elevation, could be considered in selected patients (class of recommendation IIb, level of evidence B), if adequate follow-up was arranged 5 . However, there is limited available data on its implementation in clinical practice.
The aim of this trial was to determine whether early discharge (within 48-72 h) in patients with low risk of complications after STEMI, treated with successful primary PCI, is feasible and safe, and that early discharge is equal to patients discharged, according to current local practice and the physician´s decision (usually 3rd-5th day). A third aim was to observe whether or not this approach is associated with higher incidence of complications in the following 90 days after myocardial infarction.
MATERIALS AND METHODS
This was a prospective, open-label, randomized, single centre study enrolling low risk patients with STEMI, successfully treated with primary PCI. The study was carried out in agreement with the Declaration of Helsinki and registered with ClinicalTrials.gov (identifier NCT02023983). The approval of the local Ethics committee of the Municipal Hospital Ostrava was gained prior to the start of recruitment. All individual participants included in the trial signed an informed consent at the study outset.
Calculated sample size for non-inferiority margin 10% was 126 subjects per group.
Inclusion criteria, definition of low risk and thus eligibility for enrollment in the study, are listed in Table 1 . The trial scheme is shown in Fig. 1 .
The participants were randomly (simple envelope method) assigned to two groups in a 1:1 ratio. Patients with complications or serious comorbidities, requiring additional evaluation within extended primary hospitalization at the discretion of treating physician, were excluded.
The primary end point was the composite of death, MI, unstable angina, stroke, unplanned rehospitalization, repeated target vessel revascularization and stent thrombosis within 90-days of follow-up.
The participants were admitted to the coronary care unit and then discharged from this unit or stepdown intermediate unit. No patient was transported back to the referring hospital. Echocardiography was used for evaluation of left ventricular function. Clinical check-up of patients randomized to the intervention group was performed at an outpatient visit no later than 4 days after discharge. The following 30-day and 90-day check-ups were done at the clinic or by telephone.
Statistical analysis
All patients completed the 90-day follow-up and were included in the analysis. Statistical data were processed using SPSS Statistics software package, version 22 (IBM Corporation, Armonk, NY, USA). Fischer´s exact test was used for comparison of qualitative variables. For comparison of quantitative variables we applied the MannWhitney U test or Student´s t-test (age). The normality of the data was assessed with the Shapiro-Wilk test. P<0.05 were considered statistically significant.
RESULTS
578 consecutive patients with a diagnosis of STEMI, treated with successful primary PCI, were admitted to our hospital within the period October 15, 2013 and November 23, 2016. 151 (26.1%) fulfilled the inclusion criteria, were recruited for study and randomized to two groups in a 1:1 ratio. 18% were females. The patients flow is described in Fig. 2 , where the reasons for exclusion are likewise listed. The interim results of this study have been published 6 . The baseline characteristics of the groups, the procedural data and left ventricular ejection fraction are shown in Table 2 , with the exception of body-mass index, the cohorts were similar. The most frequent risk factors were smoking, dyslipidemia and hypertension.
Inferior localization of MI clearly dominated (62.3%), the distribution of infarct related arteries between groups was slightly different (P=0.049). The radial approach as well as the use of drug eluting stents were preferred. Aspiration thrombectomy was used in less than half of the cases, glycoprotein IIb/IIIa inhibitors were administrated as bailout therapy only (14.5% vs. 16%) -no significant differences between groups. Before PCI, about half of infarct related arteries were occluded (TIMI 0 flow), on the contrary more than a quarter of patients (28.9% vs. 26.7%) showed normal (TIMI 3) flow -with no significant difference between groups. Mean left ventricular ejection fraction was practically normal and and there were no differences between groups. The length of stay was significantly (P<0.0001) shorter in the intervention group (Table 3 , Fig. 3 ).
With regard to the medication at discharge, all patients took dual antiplatelet therapy (aspirin and P2Y12 inhibitors) and a statin. There were no differences between groups in terms of β-blockers or renin-angiotensin-aldosterone system inhibitors (angiotensin-converting enzyme inhibitor or angiotensin II receptor blockers) administration (88.2% vs. 85.3%, P=0.639 and 98.7% vs. 97.3%, P=0.620, respectively).
The primary end point at 3 months occurred in 5 patients in the intervention group and 6 patients in the standard group (6.6% vs. 8%, P=0.765). There were no significant differences in the incidence of individual components of the primary endpoint. No patient died and no stroke occurred within the 90-day follow-up (Table 4) . 2 stent thromboses were registered in the group with standard discharge (19th and 88th day, the first of them 12 days after patient cessation of P2Y12 inhibitor). No adverse event occurred between early discharge and the first clinical check-up in the outpatient clinic 2-4 days after discharge. 1 symptomatic (prolonged mild wrist pain) radial artery occlusion was detected in the group with early discharge. No other complications associated with the puncture site requiring treatment occurred.
DISCUSSION
This study shows that early discharge in selected patients with STEMI treated with primary PCI is possible and safe and is not associated with higher risk of complications in the following 90 days compared to deferred discharge.
Primary percutaneous coronary intervention is currently the most effective method of reperfusion in patients presenting with acute STEMI (ref. 7 ). As a logical consequence of advances in therapy and hospital care, including early rehabilitation and mobilization, the length of hospital stay in STEMI patients has been significantly shortened within the past 50 years. An overview of the relevant literature showed wide methodological variation in given publications with e.g. 3-63% of probands fulfilling the criteria for early discharge! The current guidelines proceed from limited data derived from randomized trials.
At present, the low risk STEMI population requiring shorter in-hospital observation is well defined [8] [9] [10] [11] [12] . Grines et al. in the PAMI II study, defined low risk as: age < 70 years, left ventricular ejection fraction > 45%, single-or two-vessel disease, successful percutaneous coronary intervention and no persistent arrhythmias. STEMI patients were randomized to accelerated care (4.2 ± 2.3 days) and traditional care (7.1 ± 4.7 days) and at 6 months there were no significant differences in mortality, unstable ischaemia, reinfarction, stroke, heart failure or their combined occurrence 4 . Substantial cost reduction was demonstrated as well. De Luca et al. 11 created a practical score (Zwolle Risk Score for STEMI) for risk stratification of patients with STEMI, treated with primary PCI. They identified age, anterior infarction, Killip class, ischemic time, IGT -impaired glucose tolerance, TIA -transient ischemic attack, LAD -left anterior descending artery, C -circumflex branch, M -marginal branch, RCA -right coronary artery, GP IIb/IIIa inhibitors -glycoprotein IIb/IIIa inhibitors, EF -ejection fraction postprocedural TIMI flow in infarct related artery and multi-vessel disease as independent predictors of 30-day mortality. Score ≤ 3 designates low-risk patients. In recent years, several randomized trials have shown the possibility of length of stay shorter than 72 h. Kotowycz et al. 13 , Azzalini et al. 14 and Jirmář et al. 15 provide evidence of the feasibility of early discharge in their small studies (with 54-100 probands). Noman et al. carried out a retrospective analysis of 2448 STEMI patients treated with primary PCI and surviving to hospital discharge 16 . Patients with TIMI 3 flow in infarct related artery and without haemodynamic or arrhythmic complications were considered for early discharge at the discretion of the attending physician: a total of 1542 patients (63%) were discharged within 2 days of admission (early discharge group) and the remaining 37% after 2 days (late discharge). The 30-day post-discharge mortality rate was 0.71% in the early group and 1.66% in the late group. During a mean follow-up of 584 days, mortality was 4.3% vs. 12.3% (P<0.0001). To the best of our knowledge only two larger randomized studies have been published on this issue: Melberg et al. 17 randomized 215 patients to either early discharge (≤ 3 days) or usual routine discharge. During follow-up there were no deaths, and similar readmission rate (3.7% vs. 2.8%, P=0.69) in the early vs. usual discharge group respectively. No differences in the 30 days health status measurements were registered. In a recent large trial, Satılmısoglu et al. 18 randomly assigned 769 probands with STEMI to early (within 48 to 56 h of uneventful course) or standard discharge group. The inclusion criteria were as follows: acute STEMI, a successful primary PCI procedure, an uneventful 24-hour follow-up period, single epicardial artery to be treated. Primary outcomes were all-cause mortality and readmission at 30 days. There were no significant differences in mortality or readmissions between groups (P=0.684 and P=0.061, respectively) and the patients reported similar health status at 30 days.
In contrast to Melberg and Satılmısoglu´s studies we extended the follow-up to 90 days and our study confirmed the intermediate-term safety of the early discharge of selected low-risk patients with STEMI within 48-72 h after admission. Our results further support the recently released new version of ESC guidelines for STEMI (ref. 19 
)
in terms of the level of evidence for the strategy with the shorter recommended length of hospital stay (48-72 h).
However, we agree with Azzalini et al. that even earlier discharge within 48 h is unreasonable 14 . It should be stressed that the shorter uneventful hospital stay provides only limited time for proper patient rehabilitation, education and titration of medication. It is therefore advisable to carry out early clinical post-discharge check-up and arrange subsequent regular care, as we did in our study.
The limitation of this trial is the single centre character and limited patient sample. Because of various reasons calculated sample size was not reached, so the statistical power could be questioned.
Further trials are needed to evaluate whether less strict criteria (multivessel disease, more depressed left ventricle function, older population) could be applied for selection of patients in this setting.
CONCLUSION
This prospective, open-label, randomized study showed that early discharge (within 48 -72 h) in selected low risk patients after STEMI treated with successful primary PCI is feasible and safe. This strategy applies to more than a quarter of all STEMI patients and may be adopted in everyday clinical practice, provided the appropriate follow-up management is arranged to ensure adequate secondary prevention measures.
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